Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CD3+/CD19+ cell-depleted autologous hematopoietic stem cells

A preparation of autologous hematopoietic stem cells (HSCs) that have been selectively depleted of CD3-positive (CD3+) T cells and CD19-positive (CD19+) B cells, with potential immune reconstituting activity. Upon administration, the CD3+/CD19+ cell-depleted autologous HSCs are used for autologous stem cell transplant (ASCT) and may allow for rapid and sustained engraftment and immune reconstitution without the autoreactive CD3+ T cells and CD19+ B cells. This may alleviate manifestations of autoimmune diseases such as systemic lupus erythematosus (SLE) and systemic sclerosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CD3+/CD19+ cell-depleted HSCs
CD3+/CD19+ cell-depleted autologous HSCs
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search